Anti-nucleolin aptamer AS1411: an advancing therapeutic

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Nucleolin is overexpressed on tumor cell membranes, making it a prime target for cancer therapy.
• Nucleolin's role in angiogenesis and tumorigenesis highlights its significance in cancer progression.
• Selected pathogens utilize nucleolin for cellular entry, indicating its broad biological relevance.

Purpose of the Study:

• To evaluate the potential of the nucleolin-targeting aptamer AS1411 in cancer therapy.
• To explore AS1411's efficacy, safety profile, and potential for drug and nanoparticle conjugation.
• To assess AS1411's utility in cancer diagnosis through enhanced detection capabilities.

Main Methods:

• AS1411, a guanosine-rich oligonucleotide aptamer, was designed to bind nucleolin.
• The aptamer's internalization in tumor cells and localization to nucleolin-expressing cells were assessed.
• AS1411's safety profile and efficacy were evaluated in preclinical models of leukemia and renal cell carcinoma.

Main Results:

• AS1411 demonstrated good tolerability at therapeutic doses and selective localization to tumor cells.
• The aptamer showed efficacy in relapsed acute myeloid leukemia and renal cell carcinoma with mild to moderate side effects.
• AS1411 can be conjugated to drugs and nanoparticles for targeted delivery and enhanced diagnostic capabilities.

Conclusions:

• AS1411 is a promising targeted therapeutic agent for cancers overexpressing nucleolin.
• Its ability to be conjugated offers potential for improved drug delivery and reduced systemic toxicity.
• AS1411 holds potential for revolutionizing cancer diagnosis and treatment strategies.